Introduction {#S0001}
============

Around 60% of invasive breast cancers are stage II--III according to the AJCC TNM staging system and approximatively 85% are ductal type and chemosensitive.[@CIT0001],[@CIT0002] In primary non-operable breast cancers, neoadjuvant chemotherapy is recommended either to reduce tumor volume for an R0 conservatory or radical resection or to treat a micro-metastatic presumed disease and to improve survival without relapse.[@CIT0003],[@CIT0004] Moreover, neoadjuvant treatment offers the possibility to evaluate tumor's biological response.[@CIT0005] Standard neoadjuvant chemotherapy comprises three to four sequential courses of an anthracycline-containing regimen and three to four cycles of q3w docetaxel (Dtx).[@CIT0006] Addition of taxanes to anthracyclines in the neoadjuvant setting improves the response, docetaxelbeing the first level of recommendation.[@CIT0007] Recently, weekly 90 mg/m^2^ paclitaxel (Ptx) and 100 mg/m^2^ q3w Dtx were demonstrated to be equivalent in adjuvant setting in breast cancer.[@CIT0008] Chemotherapy efficacy depends on dose intensity, representing the amount of the chemotherapeutic agent (in mg) divided by the size of the patient (in m^2^ of body surface area) per period of time (in weeks) over which the treatment is given, referenced against a standard regimen and which is correlated to the complete pathologic response rate, a surrogate of relapse-free survival for highly proliferative tumors.[@CIT0009] Several studies have evaluated the benefit of weekly Ptx in neoadjuvant setting. Weekly Ptx is better tolerated than every 3 weeks Dtx administration and the premises for 100% intensity dose are higher.[@CIT0010]

In this retrospective analysis, we evaluated the efficacy and toxicity of weekly Ptx compared with Dtx every 3 weeks in preoperatory administration.

Methods {#S0002}
=======

We analyzed the files of adult patients (pts) with stage IIB--IIIB invasive breast cancers referred for neoadjuvant, sequential, taxane-containing chemotherapy to the Institute of Oncology "Prof Dr Alexandru Trestioreanu" and Oncofort Clinic, Bucharest, between January 2008 and January 2017. All patients provided written consent for invasive procedures and for the prospective collection of their data. The study was conducted in accordance with the Declaration of Helsinki and approved by the review boards of both institutions.

Clinical TNM classification was run according to the AJCC 7th edition.[@CIT0011] Tumors were graded according to the Elston and Ellis system, which involves ductoglandular differentiation, nuclear pleomorphism and mitotic index.[@CIT0012] Positivity for the estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) were considered according to the ASCO and CAP guidelines through the time.[@CIT0013],[@CIT0014]

Systemic treatment followed European guidelines at the time, and the selected files noted the recommended regimen in dose per square meter, the rhythm of administration and the total dose provided and real times of administration.

Among the exclusion criteria were metastatic or inoperable disease, bilateral involvement, antecedents of metachronous breast cancer and wall chest irradiation as well as changes in the type of taxane regimen or split courses of chemotherapy before and after surgery. The measurable outcomes were, as a primary objective, the type and rate of the pathologic response and as secondary objectives, the rate of grade III--IV adverse events according to CTCAE v4.03, median dose intensity and rate of 100% intensity dose, regardless of backbone chemotherapy.[@CIT0015],[@CIT0016]

Assessment of histopathological response to chemotherapy was adapted from the Chevallier criteria: complete response if there was an absence of invasive elements, partial response if stromal alterations display signs of regression and no response if there were no changes in histological tumor appearance.[@CIT0017]

Statistical analyses were ran using SPSS 22 version (IBM Corporation, Armonk, NY, USA). To run comparisons between the subgroups, nonparametric tests were employed and variables that predicted pathologic response were identified by logistic regression.

All statistical tests were two-sided, and a P-value \<0.05 was considered to be significant.

Results {#S0003}
=======

After removing missing data (incomplete immunohistopathological information, partial information about the chemotherapeutical agents, no information about the surgical specimen histopathological and immunohistochemical parameters) of the 68 cases analyzed, 47 were found eligible. Median age was 56 years (34--73 years), cTNM stage was III A-B in 25 pts (53.2%) of which 48.93% (23 pts) had tumors larger than 50 mm and 38 pts (80.8%) displayed clinically significant lymph node involvement. Based on biopsy specimens, the histology was mainly ductal invasive carcinoma (33 pts, 70.21%), tumor grades were split equally as G2 and G3 (40.4%, 19 pts each) and the immune-phenotype distribution was as follows: 25.33% (12 pts) luminal A, 42.55% (20 pts) luminal B, 6% (3 pts) triple negative and 19% (9 pts) displaying HER2 overexpression ([Table 1](#T0001){ref-type="table"}).Table 1Tumor and Population CharacteristicsVariableAll PopulationN=47 (100%)Dtx GroupN=24 (51.1%)Ptx GroupN=23 (48.9%)p-valueAge at diagnostic Median, range (years)56\[34--73\]50.5\[34--71\]58\[34--73\]0.150Personal history of cancer No45\[95.7%\]23\[95.8%\]22\[95.7%\]0.115 Yes2\[4.3%\]1\[4.2%\]1\[4.2%\]Family history of cancer No39\[83%\]19\[79.4%\]20\[87%\] Yes8\[17%\]5\[20.8%\]3\[13%\]0.477Breast quadrant External25\[53.2%\]13\[56.5%\]12\[54.5%\]0.368 Internal13\[27.7%\]8\[34.8%\]5\[22.7%\] Central7\[14.9%\]2\[8.7%\]5\[22.7%\]Laterality Right20\[42.6%\]9\[37.5%\]11\[47.8%\]0.474 Left27\[57.4%\]15\[62.5%\]12\[52.2%\]Tumor's clinical diameter Median, range45\[10--110\]40\[10--110\]50\[30--80\] ≤20mm3\[6.4%\]3\[12.5%\]0\[0%\]0.185 21--50mm27\[57.4%\]12\[50%\]15\[65.2%\] \>50mm17\[36.2%\]9\[37.5%\]8\[34.8%\]Tumor's clinical shape Round regular5(10.6%)3(12.5%)2(8.7%)0.914 Irregular36(76.6%)18(75%)18(78.3%) Inflammatory6(12.8%)3(12.5%)3(13%)cT T11(2.1%)1\[4.2%\]0\[0%\]0.424 T222(46.8%)11\[45.8%\]11\[47.8%\] T317(36.2%)7\[29.2%\]10\[43.5%\] T47\[14.9%\]5\[20.8%\]2\[8.7%\]Lymph-nodes' clinical status N09\[19.1%\]3\[12.5%\]6\[27.3%\]0.384 N125\[53.2%\]15\[62.5%\]10\[45.5%\] N212\[25.5%\]6\[25%\]6\[27.3%\]cTNM Stage I6\[12.8%\]2\[8.3%\]4\[17.4%\]0.626 Stage II16\[34%\]9\[37.5%\]7\[30.4%\] Stage III25\[53.2%\]13\[54.2%\]12\[52.2%\]Menopausal status Premenopausal16(34.8%)10(43.5%)6(26.1%)0.216 Postmenopausal30(65.2%)13(56.5%)17(73.9%)Tumor's grade G11\[2.1%\]0\[0%\]1\[6.3%\]0.123 G219\[40.4%\]14\[60.9%\]5\[31.3%\] G319\[40.4%\]9\[39.1%\]10\[62.5%\]ER Median, range50\[0--98\]65\[0--98\]30\[0--90\]0.028 0%5\[10.6%\]3\[12.5%\]2\[12.5%\]0.970 1--10%3\[6.4%\]2\[8.3%\]1\[6.3%\] \>10%32\[68.1%\]19\[79.2%\]13\[81.3%\]PgR Median, range15\[0--92\]17.5\[0--92\]10\[0--70\]0.416 0%10\[21.3%\]8\[33.3%\]2\[12.5%\]0.819 1--10%10\[21.3%\]4\[16.7%\]6\[37.5%\] \>10%20\[42.6%\]12\[50%\]8\[50%\]HER2 neg30\[63.8%\]18\[75%\]12\[80%\]0.010 pos9\[19.1%\]6\[25%\]3\[20%\]Ki67 Median, range25\[5--75\]32.5\[5--75\]18\[5--65\]0.003 \<20%8\[17%\]5\[20.8%\]3\[21.4%\]0.991 20--60%27\[57.4%\]17\[70.8%\]10\[71.4%\] \>60%3\[6.4%\]2\[8.3%\]1\[7.1%\]Phenotype Luminal A12\[25.3%\]7\[29.2%\]5\[25%\]0.545 Luminal B20\[42.5%\]8\[33.3%\]12\[60%\] HER2 overexpressing/amplified9\[19.1%\]6\[25%\]3\[15%\] TN3\[6.4%\]3\[12.5%\]0\[0%\]Backbone CHT regimen FEC10011\[23.4%\]11\[45.8%\]0\[0%\]\<0.0001 EC9025\[53.2%\]3\[12.5%\]22\[95.7%\] AC6010\[21.3%\]9\[37.5%\]1\[4.3%\] CMFq4w1\[2.1%\]1\[4.2%\]0\[0%\]Type of CHT sequence 4AC60+12Ptx 80--90mg/m^2^1\[2.1%\]-1\[4.4%\]\<0.0001 3--4 EC90 +9--12 Ptx 80--90mg/m^2^22\[46.8%\]-22\[95.6%\] 4AC60/EC90/FEC100+4Dtx100mg/m^2^23\[48.9%\]23\[95.8%\]- 4CMFq4W+2Dtx100mg/m^2^1\[2.1%\]1\[4.2%\]-[^1]

Twenty-four pts (51.01%) received q3w Dtx 75--100 mg/m^2^ and 23 pts (48.9%) received weekly 80--90 mg/m^2^ Ptx, and most of these represented the second sequence after a principally anthracycline-containing regimen (45 pts) ([Table 1](#T0001){ref-type="table"}). Significant differences between the two groups were registered only regarding the ER expression (p=0.028), HER2 positivity (p=0.001), medina Ki67 (p=0.003) and backbone chemotherapy (p\<0.0001). Even though there was no statistical significance between the two groups in terms of immunophenotypes' representation (p=0.545), the choice of docetaxelseems to be more frequent than aclitaxel, mostly in triple-negative cases ([Figure 1](#F0001){ref-type="fig"}) Ptx regimen was more frequent in ER less-expressing tumors (median ER 30% vs 65% in the Dtx group), while higher HER2 expression (p=0.10) and Ki67 value (median 32.5% Dtx vs 18%Ptx) were found in patients who have received Dtx regimen ([Table 1](#T0001){ref-type="table"}).Figure 1Taxane regimen prescription according to surrogate breast cancer phenotypes.**Abbreviations:** BC, breast cancer; Dtx, docetaxel; Ptx, paclitaxel; HER2 pos, HER2-positive breast cancer; Lum A, luminal A breast cancer; Lum B, luminal B breast cancer; TN, triple-negative breast cancer.

The median duration of taxane sequence was 83 days, 65.08 days (21--87) in the Dtx group and 81.87 days (28--105) in the Ptx group. The average intensity doses were 87.71% and 96.74% for Dtx and Ptx, respectively, and the 100% intensity dose rate was 20.8% for Dtx and 87% for Ptx (p=0.001) ([Figure 2](#F0002){ref-type="fig"}).Figure 2Dose-intensity categories for the Dtx/Ptx subgroups.**Abbreviations:** Dtx, docetaxel; Ptx, paclitaxel.

Grade 3--4 toxicity rates were 12.5% (3 pts) in patients treated with Dtx compared with 13% (3 pts) in the Ptx group (p=0.64). Dtx toxicities reported were predominantly digestive events, diarrhea and abdominal pain in 33% of cases (8 pts) and weekly Ptx toxicities reported were predominantly peripheral neuropathy in 34.8% of cases (8 pts). Hematological toxicity of all grades was registered in 25% (6 pts) of the Dtx group and 56% (13 pts) of the Ptx group, of which there was only one case of febrile neutropenia in the first group; 95.83% (23 pts) received primary prophylaxis by GCSF in the Dtx group and 43.47% (10 pts) received the same in the Ptx group ([Figure 3](#F0003){ref-type="fig"}).Figure 3Taxane regimen received in patients developing hematologic (**A**), gastrointestinal (**B**) and neurologic adverse events (**C**), all grades.**Abbreviation:** AE, adverse events.

The type of surgery was radical in 95.8% of cases (45 pts), and the pathologic response rate was 68.08% (32 pts), 15 pts (62.5%) from the Dtx group and 17 pts (73.7%) from the Ptx group (p=0.47), considering both tumors and lymph nodes. The complete pathologic response in tumor and lymph nodes was recorded in eight cases (17.02%), 3 pts (12.5%) belonging to the Dtx group and 5 pts (21.7%) belonging to the Ptx, representing 37.5% and 62.5% of complete response cases, respectively (p=0.06) ([Figure 4](#F0004){ref-type="fig"}). Changes in tumor biology in favor of aggressiveness by means of surrogate phenotype classification were identified in 5 pts (10.63%), all were in the Dtx group, with four luminal A subtypes becoming luminal B and one luminal B becoming triple negative.Figure 4Taxane regimen representation in the main categories of the pathologic response.**Abbreviations:** Dtx, docetaxel; Ptx, paclitaxel.

The pathologic response was found to correlate with cancer phenotype, PgR expression, tumor size and backbone chemotherapy ([Table 2](#T0002){ref-type="table"}), while pCR correlated with the type of taxane regimen, tumor grade and lymph node involvement ([Table 3](#T0003){ref-type="table"}).Table 2Correlation Between Pathologic Response and Histologic or Treatment VariablesVariableOdd Ratio95% CIpBC phenotype1.631\[0.149--17.872\]0.044PgR expression0.031\[0.02--3.171\]0.005Clinical tumor size0.035\[0.01--1.66\]0.04Regimen associated anthracycline vs non anthracycline1\[NR −2.057\]0.012[^2] Table 3Correlation Between pCR and Clinical, Histologic and Treatment Variables; p =0.09VariableOdd Ratio95% CIpTaxane regimen Dtx vs Ptx0.062\[0.001--5.993\]0.02Tumor's grade3.51\[0.158--77.854\]0.042Clinical lymph node involvement2.73\[0.114--65.266\]0.053[^3]

Discussion {#S0004}
==========

To date, no prospective study has compared paclitaxel and docetaxelin a neoadjuvant setting in breast cancer, and few retrospective studies have addressed this question. Our study revealed a higher tumor pathologic response rate and stromal changes as criteria of pathologic response, in patients receiving paclitaxel regimen. Moreover, the percentage of full dose administration, until the planned final course of chemotherapy, was higher in the same subgroup (87% vs 20.8%, p=0.001), and the pathologic response per se significantly correlated with the type of taxane regimen. The toxicity profile also favored weekly taxane administration, even though grade 3--4 neurological toxicity was non-negligible (34.8%).

Regarding the choice of weekly administration of Ptx, this posology and Dtx every 3 weeks were equivalent and superior to Ptx, every 3 weeks in adjuvant setting, in a prospective study in primary operable breast cancer patients (N=4950), in terms of disease-free survival (weekly Ptx HR=1.27, 95% CI \[1.03--1.57\], p=0.006; Dtx HR=1.23, 95% CI \[1.00--1.52\], p=0.02). Overall survival improvement was registered only for weekly Ptx (HR=1.32 95% CI \[1.02--1.72\], p=0.01).[@CIT0008]

A prospective trial comparing Ptx weekly versus every 3 weeks in a neoadjuvant setting showed a clear benefit for weekly in terms of complete pathologic response (28.2% vs 15.7%, p=0.02) and a similar profile of toxicity, with a rate of grade 3 peripheral neuropathy of 13.5% and 14.2%, respectively.[@CIT0018]

Concerning the pathologic response to weekly Ptx, a retrospective analysis of 54 locally advanced, operable breast cancer cases that received four cycles of anthracyclines and 12 cycles of weekly Ptx, demonstrated impressive response rates (38.9% of cases). However, the rate of febrile neutropenia was as high as 24% (13 pts),16.7% of whom required hospitalization.[@CIT0019]

The benefit and safety of sequential neoadjuvant every 3 weeks Dtx at 100 mg/m^2^ was compared to anthracyclines only containing chemotherapy, in a randomized trial for operable breast cancer patients. In this large prospective study (N=2411) evaluating the rate of pathologic remission with neoadjuvant Dtx followed by anthracyclines, complete pathologic response was observed in 26% of Dtx cases versus 12.9% of anthracycline-alone receiving patients (p\<0.001). Alongside, a higher rate of grade 3--4 toxicities in Dtx cases, with 21% of the pts presenting febrile neutropenia.[@CIT0020]

A smaller randomized trial evaluated the efficacy of neoadjuvant sequential Dtx every 3 weeks after four cycles of an anthracycline-containing regimen versus continuing the initial protocol (CVAD, cyclophosphamide, vincristine, doxorubicin, prednisolone) for additional four cycles in responders. The trial found significantly higher pCR rates for sequential Dtx administration, doubling the rate of response (34% vs 16%, p\<0.04), but the rates of neutropenia events were higher than the anthracycline-only protocol (69% vs 46%, p\<0.001).[@CIT0021]

In the present analysis, the pathologic response was associated with immunophenotype (p=0.044).

Regarding the highly aggressive HER2-positive phenotype, a large meta-analysis, which included data from 15 randomized trials, showed superior pathologic complete response rates for neoadjuvant, sequential Ptx compared with Dtx every 3 weeks (43.4%, 95% CI \[41.1--45.7\] vs 36.6%, 95% CI \[34.3--39\], p=0.0001), regardless HER2 blockade or chemotherapy backbone used. Significantly fewer grade 3--4 neutropenic adverse events with an absolute difference of 32% (p\<0.0001) and a few higher grade 3--4 neuropathic adverse events (absolute difference of 3%, p=0.0001) were registered with Ptx.[@CIT0010]

In triple-negative breast cancer, a retrospective analysis of a small sample (N=33) in primary operable patients who underwent sequential neoadjuvant anthracyclines and taxanes---Ptx 80 mg/m^2^ weekly or Dtx at a dose of 75 mg/m^2^, q3w chemotherapy for four cycles, a complete pathological response was observed in 36% of cases (13 pts). These results translated into better five-year disease-free survival, although the effect was not statistically significant (p=0.32). Unfortunately, a direct comparison between the two taxane chemotherapy regimens was not run.[@CIT0022]

However, no significant difference in pCR response rate was reported in HER 2 (human epidermal growth factor receptor2) overexpressing tumors, in a randomized Phase II study evaluating the efficacy of 12 weekly doses of 80mg/m2 of paclitaxel versus 4 cycles of 75mg/m^2^ of docetaxel in neoadjuvant setting for stage II or IIIA breast cancer, following 4 courses of anthracycline regimen, concomitant to anti-HER2 antibody. The response rate was 46.9%, 95% CI \[33.7%--60.6%\] and 42.6% 95% CI \[29.5%--56.8%\] (p=0.67), respectively, with no difference observed, not even in the hormone receptors negative subgroup 65.4% vs 45.5%, p=0.13.[@CIT0023]

Conclusions {#S0005}
===========

In our population, the results showed a better efficacy of weekly taxane administration, even though no statistical significance was found. In general, regarding the residual disease, no differences were observed concerning any pathologic response. The impression of a better complete response after the Ptx regimen is probably due to better tolerance and to a lower rate of dose-impairing toxicities. Still, a high rate of neurologic adverse events remains and its long-term effects should be evaluated. To our knowledge, this is the first time this question is addressed in the neoadjuvant setting, even retrospectively.
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[^1]: **Abbreviations:** ER, oestrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative; FEC100, fluorouracil 500 mg/m2 + epirubicin 100 mg/m2 + cyclophosphamide 500 mg/m2; EC90, epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2; AC60, doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2; Ptx, paclitaxel; dtx, Docetaxel.

[^2]: **Abbreviations:** BC, breast cancer; PgR, progesterone receptor.

[^3]: **Abbreviation:** Dtx, docetaxel, Ptx, paclitaxel.
